Pulse: Enoxaparin anti-Xa monitoring for venous thromboembolism (VTE) prophylaxis in trauma patients

September 11, 2024

New medications and new guidelines are constantly being released. Pharmacists need a mechanism to keep up with these new medications and guidelines.

Some literature suggests that higher doses may be required to achieve anti- factor XA targets and further reduce venous thromboembolism (VTE) complication. The clinical practice algorithm from western trauma association is released in November of 2020 and was the first guideline update to recommend a higher standard initial enoxaparin dose. Current guidelines do not provide definitive recommendation regarding the utilization of therapeutic drug monitoring of enoxaparin for VTE prophylaxis. Due to the potential variation in enoxaparin dosing and monitoring practices, the purpose of this pulse is to explain the role of Anti-Xa monitoring, describe clinical efficacy of anti –xa, and discuss practical application.

Target Audience

Pharmacist

Learning Objectives

1. Explain the role of anti-Xa monitoring in guiding enoxaparin dosing for venous thromboembolism (VTE) prophylaxis in trauma patients

2.Describe the clinical efficacy of anti-Xa guided enoxaparin for VTE prophylaxis in trauma patients

3.Discuss practical applications and clinical considerations for anti-Xa guided enoxaparin VTE prophylaxis in trauma patients 

Additional Information

AttachmentSize
File Audience Disclosure slide_28.pptx460.24 KB
Course summary
Available credit: 
  • 1.00 ACPE Pharmacy
    The UPMC Center for Continuing Education in the Health Sciences is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a Provider of continuing pharmacy education.
Course opens: 
09/11/2024
Course expires: 
10/11/2024
Event starts: 
09/11/2024 - 12:30pm EDT
Event ends: 
09/11/2024 - 1:30pm EDT

New medications and new guidelines are constantly being released. Pharmacists need a mechanism to keep up with these new medications and guidelines.

Some literature suggests that higher doses may be required to achieve anti- factor XA targets and further reduce venous thromboembolism (VTE) complication. The clinical practice algorithm from western trauma association is released in November of 2020 and was the first guideline update to recommend a higher standard initial enoxaparin dose. Current guidelines do not provide definitive recommendation regarding the utilization of therapeutic drug monitoring of enoxaparin for VTE prophylaxis. Due to the potential variation in enoxaparin dosing and monitoring practices, the purpose of this pulse is to explain the role of Anti-Xa monitoring, describe clinical efficacy of anti –xa, and discuss practical application.

UPMC Presbyterian
Pittsburgh, PA
United States

Ahmadbahi Vahorasarfarj, PharmD

 

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Pharmacy (CPE)

This knowledge-based activity provides 1.0 contact hours of continuing pharmacy education credit.

 

Available Credit

  • 1.00 ACPE Pharmacy
    The UPMC Center for Continuing Education in the Health Sciences is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a Provider of continuing pharmacy education.
Please login or register to take this course.